Abstract
The greatest challenges in tuberculosis (TB) vaccine development include optimization of vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. In this study, we examined the immunogenicity and protective efficacy of DNA vaccine (pVAX1-ESAT6) expressing ESAT6 protein and its booster effects in mice for control tuberculosis. The results showed that ESAT6 DNA vaccine led to a dramatic augmentation of humoral and cellular responses. The novel immunogenic ESAT6 DNA vaccine revealed in this study provided a new candidate target for tuberculosis vaccine development. Key words: Tuberculosis, Immunogenicity, ESAT6, humoral immune, cellular immune.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
